Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2020

01-11-2020 | Vasculitis | Original Article

Cancer incidence in Behçet’s disease

Authors: Deniz Can Guven, Ertugrul Cagri Bolek, Sabri Engin Altintop, Burcu Celikten, Burak Yasin Aktas, Sedat Kiraz, İbrahim Gullu, Omer Karadag, Omer Dizdar

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2020

Login to get access

Abstract

Background

Previous studies demonstrated an increased cancer risk in autoimmune diseases. Behçet’s disease (BD) was also reported to be associated with an increased risk of cancer, although the data is limited.

Aims

In this study, we aimed to assess cancer incidence in a large cohort of BD patients and to compare with the data of the same age and gender groups.

Methods

The study cohort consisted of BD patients of > 18 years of age who were prospectively recorded in the Hacettepe University Vasculitis Center. Data on any cancer was collected from the patient files. Cancer incidence was compared with age- and gender-specific cancer incidence rates of the normal population retrieved from the 2014 Turkish National Cancer Registry (TNCR) data using standardized incidence rates (SIR).

Results

Totally, 451 adult cases with BD were included. The median age of the cohort was 43 (20–75), and 52.5% of the patients were males. Eleven cancer cases were observed during a median of 124 months follow-up. Behçet’s disease was associated with an increase in cancer risk compared with expected counts in the corresponding age and sex group (SIR 2.84, 95% CI 1.50–4.94, p < 0.001). Patients with papulopustular lesions had a trend toward a decreased risk of cancer (p = 0.060), and patients using azathioprine had a significantly decreased cancer risk (p = 0.031).

Conclusion

This study revealed BD patients had approximately three times increased cancer risk compared with corresponding age and sex groups. Besides the routine care, increased attention for cancer surveillance is required in the follow-up of BD patients.
Literature
1.
go back to reference Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341(17):1284–1291PubMed Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341(17):1284–1291PubMed
2.
go back to reference Mendes D, Correia M, Barbedo M et al (2009) Behçet’s disease – a contemporary review. J Autoimmun 32(3):178–188PubMed Mendes D, Correia M, Barbedo M et al (2009) Behçet’s disease – a contemporary review. J Autoimmun 32(3):178–188PubMed
3.
go back to reference Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14:107–119PubMed Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14:107–119PubMed
4.
go back to reference Greco A, De Virgilio A, Ralli M et al (2018) Behçet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17(6):567–575PubMed Greco A, De Virgilio A, Ralli M et al (2018) Behçet’s disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev 17(6):567–575PubMed
5.
go back to reference de Chambrun MP, Wechsler B, Geri G et al (2012) New insights into the pathogenesis of Behcet’s disease. Autoimmun Rev 11(10):687–698 de Chambrun MP, Wechsler B, Geri G et al (2012) New insights into the pathogenesis of Behcet’s disease. Autoimmun Rev 11(10):687–698
6.
go back to reference Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347–3355PubMedPubMedCentral Shalapour S, Karin M (2015) Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347–3355PubMedPubMedCentral
7.
go back to reference Zamarron BF, Chen W (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7(5):651–658PubMedPubMedCentral Zamarron BF, Chen W (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7(5):651–658PubMedPubMedCentral
8.
go back to reference Landskron G, De la Fuente M, Thuwajit P et al (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185–149185PubMedPubMedCentral Landskron G, De la Fuente M, Thuwajit P et al (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185–149185PubMedPubMedCentral
10.
go back to reference Wang J-C, Xu Y, Huang Z-M, Lu X-J (2018) T cell exhaustion in cancer: mechanisms and clinical implications. J Cell Biochem 119(6):4279–4286PubMed Wang J-C, Xu Y, Huang Z-M, Lu X-J (2018) T cell exhaustion in cancer: mechanisms and clinical implications. J Cell Biochem 119(6):4279–4286PubMed
11.
go back to reference Davoodzadeh Gholami M, Kardar GA, Saeedi Y et al (2017) Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 322:1–14PubMed Davoodzadeh Gholami M, Kardar GA, Saeedi Y et al (2017) Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol 322:1–14PubMed
12.
go back to reference Erez N, Truitt M, Olson P, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-KB-dependent manner. Cancer Cell 17(2):135–147PubMed Erez N, Truitt M, Olson P, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-KB-dependent manner. Cancer Cell 17(2):135–147PubMed
13.
go back to reference Schoppmann SF, Birner P, Stöckl J et al (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161(3):947–956PubMedPubMedCentral Schoppmann SF, Birner P, Stöckl J et al (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161(3):947–956PubMedPubMedCentral
14.
go back to reference Chang SH, Park JK, Lee YJ et al (2014) Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study. Arthritis Res Ther 16(4):428PubMedPubMedCentral Chang SH, Park JK, Lee YJ et al (2014) Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study. Arthritis Res Ther 16(4):428PubMedPubMedCentral
15.
go back to reference Jung YS, Han M, Kim DY et al (2017) Cancer risk in Korean patients with Behçet’s disease: a nationwide population-based study. PLoS One 12(12):e0190182PubMedPubMedCentral Jung YS, Han M, Kim DY et al (2017) Cancer risk in Korean patients with Behçet’s disease: a nationwide population-based study. PLoS One 12(12):e0190182PubMedPubMedCentral
16.
go back to reference Wang L-H, Wang W-M, Hsu S-M et al (2015) Risk of overall and site-specific cancers in Behçet disease: a nationwide population-based study in Taiwan. J Rheumatol 42(5):879–884PubMed Wang L-H, Wang W-M, Hsu S-M et al (2015) Risk of overall and site-specific cancers in Behçet disease: a nationwide population-based study in Taiwan. J Rheumatol 42(5):879–884PubMed
17.
go back to reference Na SJ, Kang MJ, Yu DS et al (2018) Cancer risk in patients with Behçet disease: a nationwide population-based dynamic cohort study from Korea. J Am Acad Dermatol 78(3):464–470.e462PubMed Na SJ, Kang MJ, Yu DS et al (2018) Cancer risk in patients with Behçet disease: a nationwide population-based dynamic cohort study from Korea. J Am Acad Dermatol 78(3):464–470.e462PubMed
18.
go back to reference Lin Y, Li G, Zheng W et al (2014) Behcet’s disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis 17(4):459–465PubMed Lin Y, Li G, Zheng W et al (2014) Behcet’s disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis 17(4):459–465PubMed
19.
go back to reference Cengiz M, Altundag K, Zorlu F et al (2001) Malignancy in Behçet’s disease: a report of 13 cases and a review of the literature. Clin Rheumatol 20:239–244PubMed Cengiz M, Altundag K, Zorlu F et al (2001) Malignancy in Behçet’s disease: a report of 13 cases and a review of the literature. Clin Rheumatol 20:239–244PubMed
20.
go back to reference Tada Y, Koarada S, Haruta Y et al (2006) The association of Behcet’s disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol 24(5):S115PubMed Tada Y, Koarada S, Haruta Y et al (2006) The association of Behcet’s disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol 24(5):S115PubMed
21.
go back to reference Cancer statistics of Turkey. (Ed.^(Eds) (2014) Cancer statistics of Turkey. (Ed.^(Eds) (2014)
22.
go back to reference Karadag O, Erden A, Batu ED et al (2017) FRI0342 distribution of vasculitides in Eastern Mediterranean: results of a prospective cohort. Ann Rheum Dis 76(Suppl 2):616 Karadag O, Erden A, Batu ED et al (2017) FRI0342 distribution of vasculitides in Eastern Mediterranean: results of a prospective cohort. Ann Rheum Dis 76(Suppl 2):616
23.
go back to reference International Study Group for Behçet’s D (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335(8697):1078–1080 International Study Group for Behçet’s D (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335(8697):1078–1080
24.
go back to reference Guven DC, Dizdar O, Akman AC et al (2019) Evaluation of cancer risk in patients with periodontal diseases. Turk J Med Sci 49(3):826–831PubMedPubMedCentral Guven DC, Dizdar O, Akman AC et al (2019) Evaluation of cancer risk in patients with periodontal diseases. Turk J Med Sci 49(3):826–831PubMedPubMedCentral
25.
go back to reference Dizdar O, Hayran M, Guven DC et al (2017) Increased cancer risk in patients with periodontitis. Curr Med Res Opin 33(12):2195–2200PubMed Dizdar O, Hayran M, Guven DC et al (2017) Increased cancer risk in patients with periodontitis. Curr Med Res Opin 33(12):2195–2200PubMed
26.
27.
go back to reference Pineton de Chambrun M, Wechsler B, Geri G et al (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11(10):687–698PubMed Pineton de Chambrun M, Wechsler B, Geri G et al (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11(10):687–698PubMed
29.
go back to reference Giza M, Koftori D, Chen L, Bowness P (2018) Is Behçet’s disease a ‘class 1-opathy’? The role of HLA-B*51 in the pathogenesis of Behçet’s disease. Clin Exp Immunol 191(1):11–18PubMed Giza M, Koftori D, Chen L, Bowness P (2018) Is Behçet’s disease a ‘class 1-opathy’? The role of HLA-B*51 in the pathogenesis of Behçet’s disease. Clin Exp Immunol 191(1):11–18PubMed
30.
go back to reference Ekinci NS, Alpsoy E, Karakas AA et al (2010) IL-17A has an important role in the acute attacks of Behçet’s disease. J Invest Dermatol 130(8):2136–2138PubMed Ekinci NS, Alpsoy E, Karakas AA et al (2010) IL-17A has an important role in the acute attacks of Behçet’s disease. J Invest Dermatol 130(8):2136–2138PubMed
31.
go back to reference Alpsoy E (2016) Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43(6):620–632PubMed Alpsoy E (2016) Behçet’s disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol 43(6):620–632PubMed
32.
go back to reference Talaat RM, Sibaii H, Bassyouni IH, El-Wakkad A (2019) IL-17, IL-10, IL-6, and IFN-γ in Egyptian Behçet’s disease: correlation with clinical manifestations. Eur Cytokine Netw 30(1):15–22PubMed Talaat RM, Sibaii H, Bassyouni IH, El-Wakkad A (2019) IL-17, IL-10, IL-6, and IFN-γ in Egyptian Behçet’s disease: correlation with clinical manifestations. Eur Cytokine Netw 30(1):15–22PubMed
33.
go back to reference Palipudi KM, Gupta PC, Sinha DN et al (2012) Social determinants of health and tobacco use in thirteen low and middle income countries: evidence from global adult tobacco survey. PLoS One 7(3):e33466–e33466PubMedPubMedCentral Palipudi KM, Gupta PC, Sinha DN et al (2012) Social determinants of health and tobacco use in thirteen low and middle income countries: evidence from global adult tobacco survey. PLoS One 7(3):e33466–e33466PubMedPubMedCentral
34.
go back to reference Soy M, Erken E, Konca K, Ozbek S (2000) Smoking and Behcet’s disease. Clin Rheumatol 19(6):508–509PubMed Soy M, Erken E, Konca K, Ozbek S (2000) Smoking and Behcet’s disease. Clin Rheumatol 19(6):508–509PubMed
35.
go back to reference Silveira L (1992) Smoking controls symptomatology of Behçet’s disease. Arthritis Rheum 35:12S Silveira L (1992) Smoking controls symptomatology of Behçet’s disease. Arthritis Rheum 35:12S
36.
go back to reference Yu K-H, Kuo C-F, Huang LH et al (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a Nationwide population-based dynamic cohort study in Taiwan. Medicine 95(18):e3540–e3540PubMedPubMedCentral Yu K-H, Kuo C-F, Huang LH et al (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: a Nationwide population-based dynamic cohort study in Taiwan. Medicine 95(18):e3540–e3540PubMedPubMedCentral
37.
go back to reference Aktas Cetin E, Cosan F, Cefle A, Deniz G (2014) IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behçet’s disease. Mod Rheumatol 24(5):802–807PubMed Aktas Cetin E, Cosan F, Cefle A, Deniz G (2014) IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behçet’s disease. Mod Rheumatol 24(5):802–807PubMed
38.
go back to reference Blake SJ, Teng MWL (2014) Role of IL-17 and IL-22 in autoimmunity and cancer. Actas Dermosifiliogr 105:41–50PubMed Blake SJ, Teng MWL (2014) Role of IL-17 and IL-22 in autoimmunity and cancer. Actas Dermosifiliogr 105:41–50PubMed
39.
go back to reference Takeuchi M, Kastner DL, Remmers EF (2015) The immunogenetics of Behçet’s disease: a comprehensive review. J Autoimmun 64:137–148PubMedPubMedCentral Takeuchi M, Kastner DL, Remmers EF (2015) The immunogenetics of Behçet’s disease: a comprehensive review. J Autoimmun 64:137–148PubMedPubMedCentral
40.
go back to reference Uçar F, Sönmez M, Ermantaş N et al (2016) The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene 586(2):263–267PubMed Uçar F, Sönmez M, Ermantaş N et al (2016) The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients. Gene 586(2):263–267PubMed
41.
go back to reference Xiao X, Liu L, Li W-J et al (2013) HLA-DRB1 polymorphisms and risk of cervical squamous epithelial cell carcinoma: a population study in China. Asian Pac J Cancer Prev 14(7):4427–4433PubMed Xiao X, Liu L, Li W-J et al (2013) HLA-DRB1 polymorphisms and risk of cervical squamous epithelial cell carcinoma: a population study in China. Asian Pac J Cancer Prev 14(7):4427–4433PubMed
42.
go back to reference Shuxian J, Xiaoyun C, Zhihui F et al (2014) Association of HLA-B*51:01 with papillary thyroid carcinoma in the Chinese Han population of the Shandong coastal areas. Thyroid 24(5):867–871PubMedPubMedCentral Shuxian J, Xiaoyun C, Zhihui F et al (2014) Association of HLA-B*51:01 with papillary thyroid carcinoma in the Chinese Han population of the Shandong coastal areas. Thyroid 24(5):867–871PubMedPubMedCentral
43.
go back to reference Baker GL, Kahl LE, Zee BC et al (1987) Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. Am J Med 83(1):1–9PubMed Baker GL, Kahl LE, Zee BC et al (1987) Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. Am J Med 83(1):1–9PubMed
44.
go back to reference Knight A, Askling J, Ekbom A (2002) Cancer incidence in a population-based cohort of patients with Wegener’s granulomatosis. Int J Cancer 100(1):82–85PubMed Knight A, Askling J, Ekbom A (2002) Cancer incidence in a population-based cohort of patients with Wegener’s granulomatosis. Int J Cancer 100(1):82–85PubMed
45.
go back to reference Buchbinder R, Barber M, Heuzenroeder L et al (2008) Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res 59(6):794–799 Buchbinder R, Barber M, Heuzenroeder L et al (2008) Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Care Res 59(6):794–799
46.
go back to reference Bhattacharyya B, Panda D, Gupta S, Banerjee M (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28(1):155–183PubMed Bhattacharyya B, Panda D, Gupta S, Banerjee M (2008) Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28(1):155–183PubMed
47.
go back to reference Lin Z-Y, Kuo C-H, Wu D-C, Chuang W-L (2016) Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci 32(2):68–73PubMed Lin Z-Y, Kuo C-H, Wu D-C, Chuang W-L (2016) Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci 32(2):68–73PubMed
48.
go back to reference Lin Z-Y, Wu C-C, Chuang Y-H, Chuang W-L (2013) Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci 93(8):323–328PubMed Lin Z-Y, Wu C-C, Chuang Y-H, Chuang W-L (2013) Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci 93(8):323–328PubMed
49.
go back to reference Kuo M-C, Chang S-J, Hsieh M-C (2015) Colchicine significantly reduces incident Cancer in gout male patients: a 12-year cohort study. Medicine 94(50):e1570–e1570PubMedPubMedCentral Kuo M-C, Chang S-J, Hsieh M-C (2015) Colchicine significantly reduces incident Cancer in gout male patients: a 12-year cohort study. Medicine 94(50):e1570–e1570PubMedPubMedCentral
50.
go back to reference Asmana NR (2014) Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica 2014:970315–970315 Asmana NR (2014) Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica 2014:970315–970315
51.
go back to reference Zhu Z, Mei Z, Guo Y et al (2018) Reduced risk of inflammatory bowel disease-associated colorectal Neoplasia with use of Thiopurines: a systematic review and meta-analysis. J Crohn’s Colitis 12(5):546–558 Zhu Z, Mei Z, Guo Y et al (2018) Reduced risk of inflammatory bowel disease-associated colorectal Neoplasia with use of Thiopurines: a systematic review and meta-analysis. J Crohn’s Colitis 12(5):546–558
Metadata
Title
Cancer incidence in Behçet’s disease
Authors
Deniz Can Guven
Ertugrul Cagri Bolek
Sabri Engin Altintop
Burcu Celikten
Burak Yasin Aktas
Sedat Kiraz
İbrahim Gullu
Omer Karadag
Omer Dizdar
Publication date
01-11-2020
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2020
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-020-02244-0

Other articles of this Issue 4/2020

Irish Journal of Medical Science (1971 -) 4/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.